Is NBSE stock a buy right now?
1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last twelve months. There ar...
Will NeuBase Therapeutics' stock price go up in 2022?
1 Wall Street research analysts have issued 12-month target prices for NeuBase Therapeutics' stock. Their forecasts range from $9.00 to $10.00. On...
How has NeuBase Therapeutics' stock performed in 2022?
NeuBase Therapeutics' stock was trading at $2.81 at the beginning of the year. Since then, NBSE shares have decreased by 64.4% and is now trading a...
When is NeuBase Therapeutics' next earnings date?
NeuBase Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast fo...
How were NeuBase Therapeutics' earnings last quarter?
NeuBase Therapeutics, Inc. (NASDAQ:NBSE) issued its quarterly earnings results on Thursday, December, 23rd. The company reported ($0.21) earnings p...
Who are NeuBase Therapeutics' key executives?
NeuBase Therapeutics' management team includes the following people: Dr. Dietrich A. Stephan Ph.D. , Founder, Pres, CEO & Chairman (Age 52, Pay...
Who are some of NeuBase Therapeutics' key competitors?
Some companies that are related to NeuBase Therapeutics include Applied Molecular Transport (AMTI) , ProMetic Life Sciences (PFSCF) , Atossa The...
What other stocks do shareholders of NeuBase Therapeutics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other NeuBase Therapeutics investors own include Sorrento Therap...
What is NeuBase Therapeutics' stock symbol?
NeuBase Therapeutics trades on the NASDAQ under the ticker symbol "NBSE."
Is NeuBase Therapeutics stock a Buy, Sell or Hold?
NeuBase Therapeutics stock has received a consensus rating of buy. The average rating score is and is based on 5 buy ratings, 0 hold ratings, and 0...
What was the 52-week low for NeuBase Therapeutics stock?
The low in the last 52 weeks of NeuBase Therapeutics stock was 0.89. According to the current price, NeuBase Therapeutics is 110.66% away from the...
What was the 52-week high for NeuBase Therapeutics stock?
The high in the last 52 weeks of NeuBase Therapeutics stock was 5.50. According to the current price, NeuBase Therapeutics is 18.00% away from the...
What are analysts forecasts for NeuBase Therapeutics stock?
The 5 analysts offering price forecasts for NeuBase Therapeutics have a median target of 13.60, with a high estimate of 18.00 and a low estimate of...
About NeuBase Therapeutics
Headlines
NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders.
NeuBase Therapeutics (NASDAQ:NBSE) Frequently Asked Questions
Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Invest In Growth?
Signals & Forecast
2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeuBase Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NeuBase Therapeutics stock. View analyst ratings for NeuBase Therapeutics or view top-rated stocks.
Support, Risk & Stop-loss
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Is Neubase Therapeutics Inc stock A Buy?
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Insiders are negative as most recent trades are sells in Neubase Therapeutics Inc
Neubase Therapeutics Inc holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
Golden Star Signal
In the last 100 trades there were 14.05 million shares bought and 6.41 million shares sold. The last trade was done 31 days ago by Mann William Roland who bough 60.18 thousand shares. For the period there has been more stocks bought than sold among the insiders, but most of the latest transaction have been insiders selling.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Premium Research for NBSE
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
News
NeuBase Therapeutics Inc. is a biotechnology company. It is engaged in developing antisense therapies to address genetic diseases. The company's proprietary platform includes PATrOL (TM). NeuBase Therapeutics Inc., formerly known as Ohr Pharmaceutical Inc., is based in Pittsburgh, United States.
Trending Stocks
NeuBase Therapeutics Inc is a pre-clinical stage bio-pharmaceutical company. It is engaged in the development of gene silencing therapies with its synthetic antisense oligonucleotides.
